Non-alcoholic fatty liver disease historical perspective

Jump to navigation Jump to search

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease historical perspective

CDC on Non-alcoholic fatty liver disease historical perspective

Non-alcoholic fatty liver disease historical perspective in the news

Blogs on Non-alcoholic fatty liver disease historical perspective

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

NAFLD/NASH was first described in a 1980 series of obese, non-alcoholic patients of the Mayo Clinic.[1] Since that seminal description, our understanding of NAFLD has progressed minimally. [2]

Historical Perspective

  • First introduced in 1980, NAFLD is a quite new concept. [3]
  • It is divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) primarily based on histologic findings.
  • Biopsies of NAFL may also display macrovesicular steatosis with lobular and periportal irritation however do now not display cellular injury and fibrosis (steatohepatitis), which characterizes NASH. [4]
  • NAFL has in large part been taken into consideration benign, but recent cohort studies display a high hazard for development to NASH in as much as 44% on serial biopsies at 5 years.
  • NASH reasons modern fibrosis which could result in cirrhosis and hepatocellular cancer (HCC).

References

  1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
  2. Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.
  3. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  4. Zhao ZH, Liu XL, Fan JG (2017). "[Research on the natural history of non-alcoholic fatty liver disease should be taken seriously]". Zhonghua Gan Zang Bing Za Zhi (in Chinese). 25 (2): 81–84. PMID 28297791.

Template:WS Template:WH